Therapeutic effects of Low intensity extracorporeal low energy shock wave therapy (LiESWT) on stress urinary incontinence

Cheng-Yu Long1,2,3,4,11, Kun-Ling Lin1,4,11, Yung-Chin Lee5,6,7, Shu-Mien Chuang5,8, Jian-He Lu5,7, Bin-Nan Wu9, Kuang-Shun Chueh5,10, Chin-Ru Ker1, Mei-Chen Shen5 & Yung-Shun Jua3,5,7,10*

This study aimed to evaluate the therapeutic effects of Low intensity extracorporeal low energy shock wave therapy (LiESWT) on stress urinary incontinence (SUI). The investigation was a single-arm, open-label, multicentre study conducted in Taiwan. 50 female patients with SUI received LiESWT-treated with 0.25 mJ/mm² intensity, 3000 pulses, and 3 pulses/second, once weekly for 4-weeks (W4) and 8-weeks (W8). The pad test, uroflowmetry, life quality questionnaires, and 3-day urinary diary measurement were performed before and after LiESWT intervention. The results revealed that 8-week of LiESWT treatment meaningfully improved urine leakage (pad test), maximum flow rate, post-voided residual urine, average urine volume, functional bladder capacity, urinary frequency, urgency symptom, and nocturia, which also persisted to show significant improvements at 1-month follow up (F1). Moreover, bothersome questionnaires scores were significantly improved at W4, W8, and F1 as compared to the baseline (W0). These results indicated that 8 weeks of LiESWT attenuated SUI symptoms on physical activity, reduced bladder leaks and overactive bladder (OAB), implying that LiESWT brought significant improvement in the quality of life. (ClinicalTrials.gov number, NCT04059133).

Stress urinary incontinence (SUI) is a prevalent urologic problem that is characterized by involuntary leakage of urine upon physical activity, such as exercise, exertion, sneezing, coughing, and lifting heavy objects, leading to affect a woman’s physical, psychological and social activity, and impact on her quality of life (QoL). SUI is a prevalent gyneco-urological problem worldwide, with an estimate as high as 40% in adult women with urethral sphincter deficiency4,5. Vaginal delivery, aging, obesity, and menopause are some known risk factors. SUI also causes great psychosocial and sexual distress that is both costly in terms of health care expense and the QoL. Chong and colleagues reported that approximately 13.12 billion US dollars were spent on SUI, including sanitary pads, disposable underwear, diapers, laundry, dry cleaning, treatment and diagnosis6.

A spectrum of management modalities is currently available: lifestyle intervention and pelvic floor muscle training might be effective for mild symptom; electro-stimulation, vaginal devices and urethral inserts are non-invasive and temporary symptom-control methods; bulking agents and botulinum injections are less invasive with short-term effectiveness; mid-urethral slings and colposuspension are corrective with long-term effectiveness4. Each of these methods has its strengths and limitations that should be chosen according to individual

1Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 2Department of Obstetrics and Gynecology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan. 3Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 4Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 5Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 6Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan. 7Department of Urology, Kaohsiung Medical University hospital, Kaohsiung, Taiwan. 8Translational Research Center, Cancer Center, Department of Medical Research, Kaohsiung Medical University, Kaohsiung, Taiwan. 9Department of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 10Department of Urology, Kaohsiung Municipal Tung Hospital, Kaohsiung, Taiwan. 11These authors contributed equally: Cheng-Yu Long and Kun-Ling Lin. *email: juanuro@gmail.com
needs, characteristics, disease severity, and financial considerations. Meanwhile, Food and Drug Administration (FDA) has been skeptical regarding the long-term safety of synthetic mesh use in female urogynecology. Following reclassification of the product to high risk group in 2016, all manufacturers of surgical mesh intended for female pelvic organ prolapse were ordered to stop selling and distributing in April 2019. As a result of this, surgeons seek treatment alternatives for SUI, such as Low intensity extracorporeal low energy shock wave therapy (LiESWT) in the current study.

Clinical LiESWT (2000 to 3000 pulses in 0.20–0.25 mJ/mm²) was reported to enhance wound healing, promote angiogenesis, reduce the level of oxidative stress, induce the releasing of vascular endothelial growth factor (VEGF), stimulate proliferation and differentiation of stem cells, and the effect of tissue regeneration. A vast body of evidence has reported LiESWT being effective in treating tendon-bone junction diseases, ischemic cardiovascular disorders, skin wound healing, chronic soft tissues and erectile dysfunction. With the applications of LiESWT pros pers in various fields, speculation about its use in treating SUI emerged. Importantly, the advantages of LiESWT include therapies without medication or surgery, outpatient therapies, short treatment sessions, no anesthesia required, and non-invasive outpatient therapy.

The urethral sphincteric system is critical to maintain urinary continence mostly dependent on the urethral striated muscles, but the mucosa, smooth muscle, and vascular system also play an important role. While the molecular mechanism underlying the treatment effect of LiESWT on SUI is still unclear, Zhang et al. has shown that LiESWT with 0.10–0.13 mJ/mm², 200 to 300 pulses improved bladder functions due to angiogenesis, reduced oxidative stress, and decreased inflammation reaction in rats with cyclophosphamide-induced acute interstitial cystitis. Wu et al. demonstrated that in a vaginal balloon dilation induced SUI rat model, LiESWT treatment with energy flux density of 0.06 mJ/mm², and 300 pulses at 3 Hz significantly increased urethral sphincter regeneration to restore urethral closure function, promoted VEGF expression and angiogenesis, and enhanced progenitor cell recruitment. Furthermore, in the streptozotocin (STZ) -induced diabetic underactive bladder (UAB) rat model, the LiESWT was applied toward the pelvis with 0.02 mJ/mm², and 400 shocks at 3 Hz for 4 weeks. The obtained data implied that LiESWT not only ameliorated UAB and urinary incontinence but also improved bladder function and urethral structure. Thus, in the present study, we hypothesized that clinical application of LiESWT can attenuate bladder leaks, improve overactive bladder (OAB) and promote QoL.

Results

Functional analyses on physical indicators and serum parameters of studied subjects.

Timetable design for the current clinical trial of SUI was shown in Fig. 1. A total number of 50 female subjects were enrolled in the NCT04059133 study group between 2018 and 2019. Participants aged 20–75 years who were diagnosed with involuntary leakage amount of urine ≥2 g on physical activity. The baseline characteristics of the SUI subjects at W0 were summarized in Table 1. The physical indicators, including age, height, weight, waistline, body mass index (BMI), systolic pressure, diastolic pressure, and mean arterial pressure (MAP), were shown in the normal range at W0 as listed in Table 1. The mean age of the enrolled 50 subjects was 54.00 ± 9.53 years old. Additionally, serum parameters including hemoglobin A1c, blood sugar, liver function index (glutamate oxaloacetate transaminase [GOT] and glutamate pyruvate transaminase [GPT]), renal function index (Blood Urea Nitrogen [BUN] and creatinine), and lipid profile (triglycerides, cholesterol, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]) were used to determine the baseline characteristics of SUI population. All serum parameters were also characterized for the normal range at W0 as listed in Table 1.

LiESWT decreased bladder leaks by pad test. The involuntary bladder leakage of urine on physical activity was examined by pad test performance. Pad test data revealed that the amount of bladder urine leakage by pad test was meaningfully reduced from 9.85 ± 3.06 to 3.23 ± 0.78 (p < 0.01), 3.60 ± 1.01 (p < 0.01) and 0.89 ± 0.31 (p < 0.01) grams at 4-week (W4), 8-week (W8), and 1-month follow up (F1), respectively (Table 2 and Figure 1. Timetable design for clinical trial of stress urinary incontinence (SUI).
Qmax. However, the mean of PVR was noticeably decreased from 48.54 ± 8.59 ml (W0) to 35.66 ± 4.67 ml (W4) and 32.91 ± 3.74 ml (W8). Thus, PVR significantly decreased from W0 to W4 and W8, and a significant decrease was also observed at F1 (p < 0.05; p < 0.01 VS. baseline data (W0)). N = 50.

Table 1. Baseline characteristics of stress urinary incontinence (SUI) population. Note: BMI, body mass index; MAP, mean arterial pressure; GOT, glutamate oxaloacetate transaminase; GPT, glutamate pyruvate transaminase; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Values are means ± SE.*p < 0.05; **p < 0.01 VS. baseline data (W0). N = 50.

| Parameter                  | SUI (Mean ± SE) | Range       |
|----------------------------|-----------------|-------------|
| **Physical parameter**     |                 |             |
| Female age (years)         | 54.00 ± 9.53    | 20–75       |
| Height (cm)                | 158.22 ± 6.14   |             |
| Weight (Kg)                | 60.46 ± 8.17    |             |
| BMI (kg/m²)                | 24.15 ± 2.99    | 18.5–24     |
| Waistline (cm)             | 84.83 ± 8.86    |             |
| Systolic pressure (mmHg)   | 122.55 ± 17.59  | 100–120     |
| Diastolic pressure (mmHg)  | 74.51 ± 11.15   | 60–80       |
| MAP                        | 90.52 ± 12.54   | 70–110      |
| **Serum parameter**        |                 |             |
| HbA1C (%)                  | 5.63 ± 0.42     | 4–6         |
| AC sugar (mg/dl)           | 101.59 ± 1.20   | 65–109      |
| BUN (mg/dl)                | 12.40 ± 3.12    | 8–20        |
| Creatinine (mg/dl)         | 0.66 ± 0.09     | 0.44–1.03   |
| GOT (AST) (IU/L)           | 24.42 ± 8.56    | 10–42       |
| GPT (ALT) (IU/L)           | 24.96 ± 14.08   | 10–40       |
| Triglycerides (mg/dl)      | 117.63 ± 35.42  | 35–160      |
| Cholesterol (mg/dl)        | 200.55 ± 30.64  | 140–200     |
| HDL (mg/dl)                | 58.21 ± 15.18   | 29–85       |
| LDL (mg/dl)                | 119.43 ± 30.35  | 0–130       |

Table 2. Urodynamical parameters of study population for stress urinary incontinence (SUI). Note: W, week; W0, baseline data; W4, once per week, 4 weeks of LiESWT; W8, once per week, 8 weeks of LiESWT; F1, 1-month follow up; Values are means ± SE.*p < 0.05; **p < 0.01 VS. baseline data (W0). N = 50.

| Parameter                      | SUI (Mean ± SE) | W 0 | W 4 | W 8 | F1 |
|--------------------------------|-----------------|-----|-----|-----|----|
| **Uroflowmetry data**          |                 |     |     |     |    |
| Voided urine volume (ml)       | 354.59 ± 24.59  | 352.55 ± 25.57 | 360.25 ± 29.59 | 367.98 ± 44.26 |
| Maximum flow rate (Qmax) (ml/sec) | 33.89 ± 4.67   | 32.91 ± 2.88   | 34.48 ± 4.26   | 35.96 ± 3.74   |
| Post voided residual (PVR) (ml) | 48.54 ± 8.59   | 35.66 ± 5.87*  | 28.81 ± 6.57** | 26.00 ± 6.62** |
| **3-day urinary diary data**   |                 |     |     |     |    |
| Intake (ml)                    | 1784.25 ± 88.53 | 1852.80 ± 96.72 | 1738.79 ± 85.37 | 1729.48 ± 118.51 |
| Output (ml)                    | 1751.62 ± 91.68 | 1819.70 ± 89.98 | 1771.05 ± 84.43 | 1731.77 ± 114.13 |
| Average urine volume (ml)      | 219.70 ± 11.37  | 229.31 ± 10.49 | 237.01 ± 11.56* | 232.59 ± 15.21 |
| Functional bladder capacity (ml) | 363.93 ± 15.54 | 383.47 ± 19.00* | 386.13 ± 24.62* | 379.16 ± 30.76* |
| Urinary frequency (times/24hrs) | 8.54 ± 0.31     | 7.38 ± 0.38    | 6.15 ± 0.40*    | 7.39 ± 0.46    |
| Urgency (times)                | 1.95 ± 0.31     | 0.97 ± 0.24**  | 0.83 ± 0.25**   | 0.78 ± 0.26**  |
| Nocturia (times)               | 1.12 ± 0.12     | 0.84 ± 0.13    | 0.76 ± 0.14*    | 0.74 ± 0.22*   |

*Fig. 2a). At the end of 4-week and 8-week treatment, a significant improvement in urine leakage was observed. Moreover, 67.74% of women was reported to have moderate to better improvement (>50%) after 4-week therapy, and the proportion was increased to 71.42% after 8 weeks of LiESWT treatment, and 93.33% at F1 post-treatment (Fig. 2b).

**LiESWT improved urodynamical parameters.** The analysis of urodynamical parameters was performed using uroflowmetry (voided urine volume and maximum uroflow rate [Qmax]), post-voided residual urine (PVR) and 3-day urinary diary at the W0, W4, W8 of LiESWT treatment, and F1 follow up after LiESWT. The results were shown in Table 2. There was no significant difference in the mean of voided urinary volume and Qmax. However, the mean of PVR was noticeably decreased from 48.54 ± 8.59 ml (W0) to 35.66 ± 5.87 ml (p < 0.05), 28.81 ± 6.57 ml (p < 0.01), and 26.00 ± 6.62 ml (p < 0.05) at W4, W8 and F1, respectively. These findings indicated that SUI subjects exhibited a significant decrease in PVR after LiESWT treatment.
The analysis of 3-day urinary diary data was characterized in Table 2, which revealed no meaningful difference in the amount of water intake and urine output among different groups. However, 8-week of LiESWT treatment showed significant increases in the average urine volume from 219.70 ± 11.37 ml to 237.01 ± 11.56 ml (p < 0.05). According to the 3-day urinary diary data, the functional bladder capacity was also significantly promoted from 363.93 ± 15.54 ml to 383.47 ± 19.00 ml (p < 0.05), 386.13 ± 24.62 ml (p < 0.05) and 379.16 ± 30.76 ml (p < 0.05) at W4, W8 and F1, respectively. The mean times of the urinary frequency (times/24hrs) was reduced from 8.54 ± 0.31 to 6.15 ± 0.52 (p < 0.05) times at W8. The mean times of the urgency was suppressed from 1.95 ± 0.31 times to 0.97 ± 0.24 times (p < 0.01), 0.83 ± 0.25 times (p < 0.01) and 0.78 ± 0.26 times (p < 0.01) at W4, W8 and F1, respectively. Moreover, the nocturia was noticeably decreased from 1.12 ± 0.12 times to 0.76 ± 0.14 times (p < 0.05) and 0.74 ± 0.22 times (p < 0.05) at W8 and F1, respectively. Based on the 3-day urinary diary, the mean value of daytime urinary frequency, urgency and nocturia was also reduced at 8-week of LiESWT.

LiESWT improved SUI symptoms and promoted the QoL. We also investigated the relationship between LiESWT treatment and overactive bladder (OAB) as well as involuntary leakage of urine on physical activity. Subjective evaluation using Overactive Bladder Symptom Scores [OABSS], International Consultation on Incontinence Questionnaire-Short Form [ICIQ-SF], Urogenital Distress Inventory [UDI-6]-Short Form, and Incontinence Impact Questionnaire-7 [IIQ-7] score questionnaires revealed significant improvement at the end of 4-week, 8-week treatment and 1-month follow up after the last treatment (Fig. 3). The OABSS score was also significantly lessened from 6.10 ± 0.38 to 4.49 ± 0.43 (p < 0.05), 3.74 ± 0.46 (p < 0.01) and 3.80 ± 0.72 (p < 0.01), at W4, W8 and F1, respectively. The ICIQ-SF score was noticeably decreased from 10.54 ± 0.56 to 7.44 ± 0.62 (p < 0.01), 6.20 ± 0.77 (p < 0.01) and 4.40 ± 0.88 (p < 0.01) at W4, W8 and F1, respectively. The UDI-6 score was lessened from W0 7.28 ± 0.44 to 4.40 ± 0.46 (p < 0.01), 3.54 ± 0.57 (p < 0.01) and 3.20 ± 0.63 (p < 0.01) at W4, W8 and F1, respectively. The IIQ-7 score was decreased from W0 7.44 ± 0.69 to 4.20 ± 0.60 (p < 0.05), 3.31 ± 0.77 (p < 0.01) and 1.95 ± 0.61 (p < 0.05) at W4, W8 and F1, respectively. In examining questionnaire data, it was found that the OAB symptoms and bothersome questionnaire scores (OABSS, ICIQ-SF, UDI-6, and IIQ-7) were significantly reduced after LiESWT treatment.
The treatment effects of LiESWT for SUI alone or mixed UI patients. The effects of LiESWT, detailed records and statistics must be made. The detailed analysis presented potential treatment and 93% at 1-month follow up post-treatment (Fig. 2). LiESWT treatment (0.25 mJ/mm², 3000 pulses, once/week) for 4 to 8 weeks demonstrated significant improvement in incontinence symptoms. Sixty-eight percent of the study cohort reports showed moderate or better symptom improvement at the end of 4-week treatment. This number was increased to 72% after 8-week treatment and 93% at 1-month follow up post-treatment. According to questionnaire scores and the 3-day urinary diary data, the results indicated that LiESWT treatment improved bladder leakage and bladder activity symptoms, including urinary frequency, nocturia, urgency, and urgency incontinence.

Safety of LiESWT treatment. For the safety concern, LiESWT treatments were well tolerated by all the subjects in this study. No significant adverse effect associated with LiESWT, such as intolerable pain, hematuria or skin ecchymosis, was reported.

Short graphic abstract of a proposed model of the potential effect of LiESWT. The above findings led to a proposed model of the potential effect of LiESWT on bladder leakage of SUI subjects, as presented in Fig. 4. The urethral sphincteric system is critical to maintain urinary continence, mostly depending on the urethral striated muscles, but the mucosa, smooth muscle, and vascular system also play an important role, where SUI is defined as involuntary leakage of urine on physical activity, including exercise, exertion, sneezing, coughing, or lifting heavy objects. The clinical LiESWT was applied with 0.25 mJ/mm² intensity, 3000 pulses of shocks, and frequency of 3 pulses/second with the probe of LiESWT placed on the middle, the left side and the right side of the labium minor. The results revealed that LiESWT attenuated the syndrome of SUI, including bladder leaks, urinary incontinence, urgency, frequency, and nocturia after 8 week treatment, improved overactive bladder (OAB), which brought meaningful improvement in QoL.

Discussion

Our investigation demonstrated that at the end of 4-week treatment, there were significant improvements in PVR, functional bladder capacity, urine leakage, and urgency symptom. Besides, at the end of 8-week treatment, significant improvements were observed in PVR, functional bladder capacity, urine leakage, urgency frequency, urgency symptom, and nocturia. Moreover, PVR, functional bladder capacity, urine leakage, urgency symptom, and nocturia persisted to show significant improvements at 1-month follow up. The above findings indicated that clinical application of LiESWT attenuated SUI symptom on physical activity, reduced bladder leaks and overactive bladder (OAB), improved pelvic floor tissue regeneration and promoted QoL.

Clinical trials on the safety and efficacy profile of LiESWT in treating female SUI are still not completely clear. Clinically, LiESWT has emerged in recent years to treat (1) chronic pelvic pain syndrome (CPPS) (0.10–0.25 mJ/mm², 3000 pulses, once/week, 4 weeks) to improve pain, bladder voiding and QoL; (2) erectile dysfunction (ED) (0.10–0.25 mJ/mm², 3000–6000 pulses, once/week, 4–8 weeks) to increase penile hemodynamics and induce penile tissue regeneration. In this study, the recruited subjects had normal BMI, blood pressure, renal function, liver function, blood sugar level, and lipid profiles, thus eliminating the potential confounding factors (Table 1). LiESWT treatment (0.25 mJ/mm², 3000 pulses, once/week) for 4 to 8 weeks demonstrated significant improvement in incontinence symptoms. Sixty-eight percent of the study cohort reports showed moderate or better symptom improvement at the end of 4-week treatment. This number was increased to 72% after 8-week treatment and 93% at 1-month follow up post-treatment (Fig. 2) with LiESWT, as demonstrated by significant improvement of symptom scores using OABSS, ICIQ-SF, UDI-6, and IIQ-7 (Fig. 3). This investigation was the first clinical study to report LiESWT’s treatment on female SUI. However, the study is limited by short-term follow up.

We investigated the relationship between LiESWT treatment and SUI as well as involuntary leakage of urine on physical activity. Subjective evaluation using OABSS, ICIQ-SF, UDI-6, and IIQ-7 questionnaires appraised the incontinence improvement and changes of life quality of urinary bothersome before and after LiESWT treatment, owing to clinical subjects who were diagnosed SUI alone or SUI combined with OAB. In order to clarify the effects of LiESWT, detailed records and statistics must be made. The detailed analysis presented potential treatment effects of LiESWT for SUI alone or mixed UI patients.
Since it was not easy to obtain bladder tissues in clinical trials, animal experiments were carried out to understand the molecular mechanism of SUI and LiESWT therapeutic effect. In rat animal model, using oligo microarray analysis showed that the expression of genes involved in the inflammation (Smad2, involved in the signaling pathway of the transforming growth factor β [TGF-β]), smooth muscle regulation (regulator of G-protein signaling 2 [RGS2]) and collagen metabolism (matrix metalloproteinase 13 [MMP13]) was significantly increased in the parturition-induced SUI rats30. Zhang et al. showed that LiESWT with 0.10–0.13 mJ/mm² and 200 to 300 pulses improved bladder functions, due to angiogenesis, reduced oxidative stress and decreased inflammation reaction in rats with cyclophosphamide-induced acute interstitial cystitis 21. Moreover, the effects of LiESWT with 0.12 mJ/mm² and 300 pulses suppressed overactive bladder and bladder pain by activating the expression of IL-6, NGF, and COX-2 in rats with cyclophosphamide-induced interstitial cystitis31. Wu et al. indicated that the beneficial effects of LiESWT with an energy flux density of 0.06 mJ/mm² and 300 pulses at 3 Hz significantly increased urethral muscle regeneration to restore urethral closure function, promoted VEGF expression and angiogenesis, and enhanced progenitor cell recruitment in a vaginal balloon dilation (VBD) induced SUI rat model22. Furthermore, in the streptozotocin (STZ) -induced diabetic underactive bladder (UAB) rat model, the LiESWT was applied toward the pelvis with energy flux density of 0.02 mJ/mm², and 400 shocks at 3 Hz for 4 weeks. It was found that LiESWT ameliorated UAB and urinary incontinence, and improved bladder function and urethral structure23. Additionally, understanding the biological effects of urethral striated muscle cells may expand understanding of urethral anatomy and increase treatment options for SUI. PERK/ATF4 pathway was involved in myotube formation, and rat myoblast cells were activated by LiESWT to form myotubes. The finding suggested that the effect of utilizing LiESWT stimulates urethral myogenesis through PERK/ATF4 pathway32. This information may help to further refine the use of LiESWT in the clinical trial of medicine.

SUI is a common and disturbing disease with a spectrum of management modalities, including pelvic floor exercise, biofeedback training, electrostimulation, vaginal laser therapy, and bulking agent injections. The various options imply that no single effective treatment could be universally recommended to the patients. Using surgical intervention that augments urethra stability with native tissue or synthetic mesh seems to work well. Consensus statement of the European Urology Association acknowledged that synthetic slings for SUI are effective with acceptable morbidity in 201733. However, slings implantation still poses surgical risks and unwanted consequences, although few in number. Souders et al. analyzed more than 70,000 legal claims against synthetic mesh or sling use from 2000 to 2014, and found that the majority (63%) was related to SUI alone, from the retropubic sling procedures34. Reported complications included bladder perforation, hemorrhage, bowel injury, vaginal extrusion, de novo urgency, urinary tract infections, and voiding dysfunction, with incidence of 4.3% to 75.1%35. These concerns finally led to FDA ban on selling and distributing such products in the United States in 2019, thus warranting further search for treatment options that are both effective and safe.

For patient-centered care in our hospital, SUI patients were educated to do Kegel exercise as a lifestyle modification. If there is no obvious improvement after 3 months of conservative treatment, then LiESWT treatment was advised for those SUI subjects. Therefore, our SUI subjects received both LiESWT and Kegel exercise. Kegel exercise can strengthen pelvic floor muscle and enhance elasticity, which supports the uterus, bladder, small intestine and rectum to prevent leaking urine. Several previous studies showed Kegel exercise takes more than sixth month to make significant improvement. Kegel Exercise is also less effective for moderate to severe incontinence.
inability to comprehend or comply with instructions. Injection, irradiation, shockwave or electrostimulation in the past 12 months, (10) urinary catheterization, urinary tract infection (interstitial cystitis, urethral syndrome or painful bladder syndrome), drug or alcohol abuse (Alcohol Use Disorders Assessment Test >3, 20–75 years who were diagnosed with SUI for more than 3 months. Major exclusion criteria included the followings: (1) urinary tract infection detected at screening, recurrent urinary tract infections (more than 3 episodes in the past 3 months), (2) comorbidities relevant to OAB (diabetes mellitus, spinal cord injury, stroke or neurogenic diseases), (3) severe cardiovascular diseases, (4) coagulopathy, (5) liver failure, (6) renal failure, (7) chronic urinary tract infection (more than 3 episodes in the past 3 months, (2) comorbidities relevant to OAB (diabetes mellitus, spinal cord injury, stroke or neurogenic diseases), (3) severe cardiovascular diseases, (4) coagulopathy, (5) liver failure, (6) renal failure, (7) chronic urinary tract infection, (8) lower urinary tract surgeries in the past 6 months, (9) perineal operations, intravesical injection, irradiation, shockwave or electrostimulation in the past 12 months, (10) recent catheterization, urologic malignancy, neurogenic bladder, significant bladder outlet obstruction, kidney stones, chronic pelvic pain, or inability to comprehend or comply with instructions.

Materials and Methods

Eligibility of Subject. This clinical trial was a single-arm, open-label, prospective study and performed with the approval of the institutional review board of a tertiary medical center. All participants provided informed consent, as approved by the Kaohsiung Medical University Hospital Institutional Review Board and was adhered to the Declaration of Helsinki (clinical trial registration No. KMUHIRB-F(II)-20180010), before entering the study and had a complete medical history and physical examination in the office of hospital. This study was also registered at clinicaltrials.gov (NCT04059133) and the date of registration was August 16, 2019. Female subjects aged 20–75 years who were diagnosed with SUI for more than 3 months. Major exclusion criteria included the followings: (1) urinary tract infection detected at screening, recurrent urinary tract infections (more than 3 episodes in the past 3 months), (2) comorbidities relevant to OAB (diabetes mellitus, spinal cord injury, stroke or neurogenic diseases), (3) severe cardiovascular diseases, (4) coagulopathy, (5) liver failure, (6) renal failure, (7) chronic urinary tract infection, (8) lower urinary tract surgeries in the past 6 months, (9) perineal operations, intravesical injection, irradiation, shockwave or electrostimulation in the past 12 months, (10) recent catheterization, urologic malignancy, gross hematuria, significant bladder outlet obstruction, kidney stones, chronic pelvic pain, or inability to comprehend or comply with instructions.

Physical Indicators and Biochemical Parameters of Study Subjects. The physical and serum parameters of metabolic syndrome were associated with the symptoms of SUI. We analyzed the physical indicators, including age, height, weight, waistline, body mass index (BMI), systolic pressure, diastolic pressure, and mean arterial pressure (MAP). Additionally, we also examined biochemical parameters including hemoglobin A1c (glycated hemoglobin; HbA1C), blood sugar, glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) for liver function index, Blood Urea Nitrogen (BUN) and creatinine for renal function index, lipid profile on triglycerides, cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) to investigate the baseline characteristics of SUI population.

Pad Test for the Evaluation of SUI. The pad test was applied as a non-invasive diagnostic to quantify the severity of SUI. The purpose of pad test in this study was to evaluate the effect of LiESWT on reducing urinary incontinence symptoms in women with SUI. Previously reported studies recommended a volume equivalent to approximately 60–80% of the functional bladder capacity. According to 3-day urinary diary data before the pad test and LiESWT, the functional bladder capacity of all subjects was determined. For the pad test, women subjects were asked to drink 1000 ml of water. A weighted pad was wearing after filling the bladder to 60–80% of the functional bladder capacity by using bladder scan sonography. In that way, the pad test could be standardization with less deviation. The subjects should perform physical activities (stair climbing, jumping, coughing), then the pad was weighed again. After wearing pad, the subjects were instructed to exercise for 30 minutes (stair climbing (30 ×), coughing vigorously (10 ×), jumping, running (1 minute), and washing hands in running water (1 minute)). The weights before and after exercise were used to calculate the pad absorption. For the pad test, an increase of < 2 g was represented as slight incontinence, mild incontinence (2–10 g), moderate incontinence (11 to 50 g),
and severe incontinence (>50 g)\textsuperscript{41}. The percentage (%) of improvement was calculated at 4-week (W4), 8-week (W8), and 1-month follow up (F1) after LiESWT treatment and the results were normalized with pre-treatment baseline data (W0).

**Procedure and medical information of LiESWT.** Subjects were informed of their treatment modalities including the required consent to join this study and once weekly LiESWT for 8 weeks and follow up at 4-week after completing the course of treatment (Fig. 1). Our instrumentation was the DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTron\textsuperscript{TM}, GA). The LiESWT was applied with 0.25 ml/mm\textsuperscript{2} intensity, 3000 pulses of shocks, and frequency of 3 pulses/second, as modified from previous reports\textsuperscript{8}. Subjects were poked at the left and right labia minora of the genital area, and the applicator was gently placed on the middle, the left side and the right side of the labia with 0.25 ml/mm\textsuperscript{2} intensity and 1000 pulses of shocks individually.

**Procedure of Kegel exercise.** The purpose of Kegel exercise strengthens the pelvic floor muscles and improving elasticity, which supports the uterus, bladder, small intestine and rectum to reduce urinary incontinence symptoms and prevent leaking urine in women with SUI. We educated patients how to identify pelvic floor muscles and tighten them, and to make sure pelvic muscle contractions. Initially, subjects tried to contract pelvic muscle for three seconds at a time and a relaxed for a count of three. They gradually increased the length of contractions and relaxations, worked up to 10-second contractions as well as relaxations. Kegel exercise plays the role of adjuvant therapy in combination with LiESWT.

**Uroflowmetry and measurement of PVR volume.** Before the treatment of LiESWT, uroflowmetry and PVR amount were checked to rule out voiding dysfunction. Uroflowmetry was served as a noninvasive screening test for selecting patients who should undergo more sophisticated urodynamic studies. In this study, voided urine volume and Qmax were recorded. Measurement of PVR, the amount of residual urine in the bladder after a voluntary void, was performed by Verathon BV1 9400 Bladder Scanner (Radiance Medical Systems, Kuala Lumpur, MALAYSIA). These examinations helped evaluate the therapeutic effect of LiESWT at W0, W4, and W8 of LiESWT, and F1 after LiESWT.

**Questionnaires for subjective evaluation.** Subjective evaluation using OABSS, ICIQ-SF, UDI-6, and IIQ-7 score questionnaires to evaluate the incontinence improvement and life quality of urinary bothersome after treatment. Among these questionnaires, OABSS questionnaire was applied for evaluating OAB symptoms, including daytime frequency, nocturia, urgency, and urge incontinence\textsuperscript{42}. ICIQ-SF questionnaire was used for evaluation the severity of urinary loss and quality of life for subjects with urinary incontinence\textsuperscript{43}. UDI-6 and IIQ-7 questionnaires were short forms to assess quality of life and symptoms severity for urinary incontinence in women\textsuperscript{44}.

**Therapeutic efficacy assessment for LiESWT.** To analyze the effects of LiESWT, the primary endpoints were change in pad test and questionnaires, and the secondary endpoints were change in uroflowmetry, PVR, and 3-day urinary diary at W0, W4 and W8 of LiESWT and F1 after LiESWT. SUI questionnaires included overactive bladder questionnaire short form (OABSS, ICIQ-SF, UDI-6, and IIQ-7 scores). Moreover, uroflowmetry and PVR measurements were performed to assess the urodynamic parameters at W0, W4, W8, and F1. The primary endpoint was the mean change in SUI symptoms and urodynamic parameters from the baseline to the end-of-treatment.

**Statistical analysis.** Questionnaires (OABSS, ICIQ-SF, UDI-6, and IIQ-7 scores), pad test, uroflowmetry (voided urine volume and Qmax), PVR, and 3-day urinary diary were used to assess the efficacy and safety of the pre- and post-treatments performed with LiESWT on SUI subjects. Quantitative data were represented as mean \( \pm \) standard error of mean (SEM). In order to clarify the effect of LiESWT therapy on SUI, we compared the pre- and post-treatment scores (W4 vs. W0, W8 vs W0, F1 vs W0) for intragroup of patients, not between groups of patients. Therefore, Paired t-test was used to perform a repeated measurement analysis for intragroup before/after treatment and to calculate p-values for comparison\textsuperscript{45,46} in single-arm clinical trial of the current study. For all statistical analyses, \( p < 0.05 \) was considered statistically significant. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA).

Received: 2 October 2019; Accepted: 10 March 2020; Published online: 02 April 2020

**References**

1. Hunskaar, S. et al. Epidemiology and natural history of urinary incontinence in women. *Urology* 62, 16–23 (2003).
2. Rizk, D. E. Epidemiology consequences and natural history of urinary incontinence in non-caucasian women. *Int. Urogynecol. J. Pelvic Floor Dysfunct.* 12, 413 (2001).
3. Chong, E. C., Khan, A. A. & Anger, J. T. The financial burden of stress urinary incontinence among women in the United States. *Curr. Urol. Rep.* 12, 358–362, https://doi.org/10.1007/s11934-011-0209-x (2011).
4. Prashanth, M. S. & David, M. Changes in nitrogen metabolism of the freshwater fish Cirrhinus mrigala following exposure to cypermethrin. *J. Basic. Clin. Physiol. Pharmacol.* 17, 63–70 (2006).
5. Gurok-Urganci, I. et al. Long-term Rate of Mesh Sling Removal Following Midurethral Mesh Sling Insertion Among Women With Stress Urinary Incontinence. *JAMA* 320, 1659–1669, https://doi.org/10.1001/jama.2018.14997 (2018).
6. Raswelier, J. J. et al. Shock wave technology and application: an update. *Eur. Urol.* 59, 784–796, https://doi.org/10.1016/j.euro.2011.02.033 (2011).
7. Liu, T., Shinadel, A. W., Lin, G. & Lee, T. F. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy. *Int. J. Impot. Res.* 31, 170–176, https://doi.org/10.1038/s41443-019-0113-3 (2019).
8. Mouchopoulos, G., Stamatakos, M., Mouchopoulos, D. & Tzebakis, M. Extracorporeal shock wave treatment for shoulder calcific tendinitis: a systematic review. *Stekel. Radiol.* 36, 803–811, https://doi.org/10.1007/s00256-007-0297-3 (2007).


Acknowledgements

We are grateful to Professor Chang-Hwei Chen of the University at Albany, State University of New York for his valuable comments on this manuscript. Grant numbers and sources of support: This research is supported by the grant from Ministry of Science and Technology (MOST 105-2314-B-037-043-MY3, MOST 107-2314-B-037-008, and MOST 106-2314-B-037-083), and in part by the Department of Medical Research, Kaohsiung Medical University Hospital grant (KMUH-104-4R45, KMUH-105-5R44, KMUH-106-6R60, and KMUH-107-7R60), and in part by Ministry of Health and Welfare (MOHW107-TDU-B-212-123006), and Kaohsiung Municipal Hsiao-Kang Hospital grant (Kmhk-106-008 and Kmhk-107-024) and Kaohsiung Medical University Research Center Grant (KMU-TC108A02).

Author contributions

C.Y.L., K.L.L., Y.C.L., S.M.C., J.H.L., B.N.W., K.S.C., C.R.K., M.C.S., and Y.S.J. conceived and designed the study; C.Y.L., K.L.L., Y.C.L., S.M.C., J.H.L., B.N.W., K.S.C., C.R.K., and Y.S.J. conducted review and editing; C.Y.L., K.L.L., Y.C.L., S.M.C., J.H.L., and Y.S.J. had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. C.Y.L., K.L.L., Y.C.L., S.M.C., J.H.L., and Y.S.J. wrote the paper. All authors reviewed and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Y.-S.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020